These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 30410066)

  • 21. Smoldering multiple myeloma: evolving diagnostic criteria and treatment strategies.
    Visram A; Cook J; Warsame R
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):673-681. PubMed ID: 34889380
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Plasma Levels of the Angiogenic Cytokine Endocan Are Elevated in Patients with Multiple Myeloma.
    Steiner N; Hajek R; Sevcikova S; Borjan B; Untergasser G; Göbel G; Gunsilius E
    Anticancer Res; 2018 Sep; 38(9):5087-5092. PubMed ID: 30194153
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of patients with smouldering multiple myeloma at ultra-high risk of progression using serum parameters: the Czech Myeloma Group model.
    Hájek R; Sandecka V; Špička I; Raab M; Goldschmidt H; Beck S; Minařík J; Pavlíček P; Radocha J; Heindorfer A; Jelínek T; Stejskal L; Brožová L; Ševčíková S; Straub J; Pika T; Pour L; Maisnar V; Seckinger A; Hose D
    Br J Haematol; 2020 Jul; 190(2):189-197. PubMed ID: 32163180
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is aggressive treatment of smoldering myeloma the path to curing myeloma?
    Chakraborty R; Al Hadidi S; Cliff ERS; Mohyuddin GR
    Blood Adv; 2023 Aug; 7(15):3932-3935. PubMed ID: 37196639
    [No Abstract]   [Full Text] [Related]  

  • 25. Testing Mayo Clinic's New 20/20/20 Risk Model in Another Cohort of Smoldering Myeloma Patients: A Retrospective Study.
    Tessier C; Allard T; Boudreault JS; Kaedbey R; Éthier V; Fortin F; Pavic M
    Curr Oncol; 2021 May; 28(3):2029-2039. PubMed ID: 34073289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Smoldering Multiple Myeloma: Who and When to Treat.
    Mateos MV; González-Calle V
    Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):716-722. PubMed ID: 28709797
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma.
    Boyle EM; Deshpande S; Tytarenko R; Ashby C; Wang Y; Bauer MA; Johnson SK; Wardell CP; Thanendrarajan S; Zangari M; Facon T; Dumontet C; Barlogie B; Arbini A; Rustad EH; Maura F; Landgren O; Zhan F; van Rhee F; Schinke C; Davies FE; Morgan GJ; Walker BA
    Nat Commun; 2021 Jan; 12(1):293. PubMed ID: 33436579
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients.
    González-Calle V; Mateos MV
    Eur J Intern Med; 2018 Dec; 58():57-63. PubMed ID: 29907380
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of smoldering myeloma: Recommendations of the Spanish Myeloma Group.
    Mateos MV; Bladé J; Lahuerta JJ; San-Miguel J
    Med Clin (Barc); 2017 Jun; 148(11):517-523. PubMed ID: 28341370
    [No Abstract]   [Full Text] [Related]  

  • 30. Pseudohyperphosphatemia in a patient with incidentally identified progression of smoldering myeloma.
    Francis ER; Chen F; Kidacki M; Miller R; Alkhasoneh M; Talamo G; Straub M; Klinefelter K; Kodali N; Zhu Y
    Clin Chim Acta; 2018 Dec; 487():306-308. PubMed ID: 30315756
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Smoldering Myeloma Treatment: Who, What, and When.
    Mejia Saldarriaga M; Rossi A
    Cancer J; 2021 May-Jun 01; 27(3):185-189. PubMed ID: 34549905
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma.
    Aljama MA; Sidiqi MH; Lakshman A; Dispenzieri A; Jevremovic D; Gertz MA; Lacy MQ; Buadi FK; Dingli D; Muchtar E; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Warsame R; Kourelis TV; Hwa YL; Kapoor P; Leung N; Go RS; Kyle RA; Rajkumar SV; Kumar SK
    Blood Adv; 2018 Nov; 2(22):3149-3154. PubMed ID: 30463914
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM): a practical guide to management.
    Maciocia N; Wechalekar A; Yong K
    Hematol Oncol; 2017 Dec; 35(4):432-439. PubMed ID: 27804161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Practical approach to the management of smoldering myeloma.
    Joseph NS; Lonial S
    Curr Opin Oncol; 2020 Nov; 32(6):656-663. PubMed ID: 32890022
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progressively decreasing plasma high-density lipoprotein cholesterol levels preceding diagnosis of smoldering myeloma.
    Tavori H; Ormseth MJ; Lilley JS; Papen CR; May-Zhang LS; Davies SS; Linton MF; Fazio S
    J Clin Lipidol; 2020; 14(3):293-296. PubMed ID: 32376310
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative genomic hybridisation identifies two variants of smoldering multiple myeloma.
    Rosiñol L; Carrió A; Bladé J; Queralt R; Aymerich M; Cibeira MT; Esteve J; Rozman M; Campo E; Montserrat E
    Br J Haematol; 2005 Sep; 130(5):729-32. PubMed ID: 16115129
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Smoldering multiple myeloma: natural history and recognition of an evolving type.
    Rosiñol L; Bladé J; Esteve J; Aymerich M; Rozman M; Montoto S; Giné E; Nadal E; Filella X; Queralt R; Carrió A; Montserrat E
    Br J Haematol; 2003 Nov; 123(4):631-6. PubMed ID: 14616966
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study.
    Sørrig R; Klausen TW; Salomo M; Vangsted AJ; Østergaard B; Gregersen H; Frølund UC; Andersen NF; Helleberg C; Andersen KT; Pedersen RS; Pedersen P; Abildgaard N; Gimsing P;
    Eur J Haematol; 2016 Sep; 97(3):303-9. PubMed ID: 26710662
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management.
    Rajkumar SV
    Hematology Am Soc Hematol Educ Program; 2005; ():340-5. PubMed ID: 16304401
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum markers alone can define high-risk smouldering multiple myeloma: new insights from the Czech Myeloma Group model.
    Sørrig R
    Br J Haematol; 2020 Jul; 190(2):137-138. PubMed ID: 32220013
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.